Plato Investment Management Ltd Takes Position in Thermo Fisher Scientific Inc. $TMO

Plato Investment Management Ltd acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, HoldingsChannel reports. The fund acquired 9,440 shares of the medical research company’s stock, valued at approximately $4,705,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMO. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. Legacy Wealth Managment LLC ID grew its holdings in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the period. Birchwood Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Core Wealth Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. Finally, Barclays boosted their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 in the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 0.8%

NYSE TMO opened at $590.00 on Wednesday. The stock has a market cap of $218.15 billion, a P/E ratio of 31.74, a PEG ratio of 2.39 and a beta of 0.84. The company’s fifty day simple moving average is $533.64 and its 200-day simple moving average is $508.36. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the business earned $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.